Langaware develops an AI-driven diagnostics platform that analyzes language, voice, and speech digital biomarkers to predict and monitor conditions including mild cognitive decline, Alzheimer’s disease, and Depression. The product is the result of several years of research and has been tested and proven effective in both clinical and virtual care settings in the US and Greece. The company positions its technology to help health systems, providers, and the pharma industry deliver tailored patient care and support through earlier detection. Langaware plans to use new funding to further develop its technology and product teams and to expand its presence in the US market. Founder and CEO Vassiliki Rentoumi said the investment will help unlock AI’s potential to relieve strain on healthcare systems, drive down costs, and improve access to high-quality care.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2023